Intermittent administration of parathyroid hormone improves the repairing process of rat calvaria defects: A histomorphometric and radiodensitometric study

Eduardo-de-Paula Silva 1, Daniel-Fernando-Pereira Vasconcelos 2, Marcelo-Rocha Marques 1, Marco-Antônio Dias da Silva 3, Flávio-Ricardo Manzi 4, Silvana-Pereira Barros 5

1 Department of Morphology, Division of Histology, School of Dentistry at Piracicaba, University of Campinas, Piracicaba-SP, Brazil
2 Division of Histology and Embryology, School of Biomedicine, Federal University of Piauí, Parnaíba-PI, Brazil
3 Division of Histology and Embryology, Federal University of Campina Grande, Patos-PB, Brazil
4 Department of Dentistry, Pontifical Catholic University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
5 Center for Oral and Systemic Diseases, Department of Periodontology, UNC School of Dentistry, University of North Carolina at Chapel Hill, USA

Correspondence:
Universidade Federal do Piauí - UFPI,
Campus Ministro Reis Veloso,
Colegiado de Biomedicina,
Av. São Sebastião, 2819, Reis Veloso,
Parnaíba -PI -Brazil, 64204-035,
vasoncelos@ufpi.edu.br

Abstract
Background: The aim of this study was to evaluate the effects of intermittent treatment of parathyroid hormone (PTH (1-34)) on the bone regeneration of critically-sized rat calvarial bone defects.
Material and Methods: Thirty-two male rats were trephined (4mm fullthickness diameter), in the central part of the parietal bones and divided into 2 groups of 16. The PTH group received subcutaneous injections of PTH (1-34) at 40µg/kg, 3 times a week and the control (CTL) group received the vehicle in the same regimen. The rats were sacrificed at 4 weeks post-treatment regimen, the parietal bones were extracted and samples were evaluated through histomorphometry and radiodensitometry.
Results: The histological observations showed that the PTH group presented more “island-like” new bone between the defect margins with fibrous tissues than did the CTL group. The PTH group significantly exhibited greater histologic bone formation than did the CTL group (1.5mm ±0.7; 1.9 mm ± 0.6, p<0.05/ for residual bone defect). The radiodensitometry analysis revealed significant differences among the PTH and CTL groups (2.1 Al eq. ±0.04; 1.8Al eq. ±0.06, p<0.05), demonstrating an increase in bone mineral density. The PTH treatment contributed to the bone formation with a higher amount of mineral and/or fibrous tissue when compared with the CTL group.
Conclusions: The results suggest that it was possible to increase the process of bone regeneration by accelerating the healing process in rat calvarial defects through intermittent administration of the PTH treatment.

Key words: Bone, skull, rats, bone regeneration, bone density.
Introduction
Defects in bone are frequent sequelae of pathological conditions such as tumors, cysts, infections, trauma or surgery. The slow regeneration of bone in such defects can pose therapeutic problems. Various strategies to stimulate healing of bone defects have been tested. These include autografting and allografting of bone, application of growth factors, polymeric membranes, enamel matrix derivative and others (1-3). Various drugs have been used to assist in bone regeneration, in a way stimulate bone tissue anabolism (4,5). We have demonstrated that the PTH intermittent treatment was able to prevent or minimize bone loss caused by induced periodontitis in rats (6,7) and also improved the healing fenestration bone defect in rat mandible (8). PTH functions as a major mediator of bone remodeling and as an essential regulator of calcium homeostasis, producing several distinct and independent effects on bone remodeling process, resulting in both bone formation (anabolic activity) and bone remodeling (catabolic activity), e.g. the continuous administration of PTH is characterized by large numbers of osteoclasts and enhanced osteoclast activity, rapid turnover and decrease of bone mass, while intermittent administration increases bone mass by stimulating osteoblast differentiation and prevention of osteoblast apoptosis (9).

PTH has been used successfully in the treatment of osteoporosis in humans. Intermittent administration of PTH has been proved to decrease the risk of vertebral and non-vertebral fractures and to increase the femoral and vertebral bone density with reduced or absent side effects (10). Studies have also demonstrated that the intermittent PTH treatment enhances fracture strength and callus amount in the healing of tibial fractures in rats (11), also increasing stiffness, bone density and the ultimate load in newly-formed bone after osteogenesis distraction in rats (12). Although most of these studies support a role for PTH in the treatment of osteoporosis and long bone fractures, only a few studies associated PTH treatment to calvarial healing (13,14).

Andreassen and Cacciafesta (14) reported that intermittent PTH administration enhanced mechanical strength of healing rat calvarial defects covered by expanded polytetrafluoroethylene membranes, besides having increased the dry weight of the newly-formed tissue inside the defect. Stancoven et al. (13) used a critical-size of 8mm and investigated the potential of recombinant human bone morphogenetic protein-2 soak-loaded onto an absorbable collagen sponge to induce local bone formation compared with the clinical reference demineralized bone matrix and investigated potential additive/synergistic effects of exogenous PTH.

The purpose of our study was to evaluate the effect of intermittent PTH treatment alone on critically-sized calvarial defects (4mm) in Wistar rats through histomorphometric and radiodensitometric analyses.

Material and Methods
- Animals
Thirty-two male Wistar rats, weighing an average of 250 g, were used in this study. The animals were separated randomly into two groups (16 rats per group) and kept in cages in an animal room having a photoperiod of 12 h of light with access to industrial food, close to 110 Kcal/kg of body weight; water was provided “ad libitum.” Room temperature was kept at between 22-25°C, and animals were allowed one week to adapt to the environment. The University of Campinas Institutional Animal Care and Use Committee approved the protocol under number 737-2/ UNICAMP-CEEA-IB-UNICAMP.

- Surgical Technique
The animals were anesthetized with intramuscular administration of a solution of 13 mg/Kg of 2% xylazine hydrochloride (Rompum-Bayer-São Paulo, SP, Brazil) and 33 mg/Kg of ketamine (Francotar-Virbac-Roseira, SP, Brazil). During surgery, local anesthesia (lidocaine, 1:100.000 epinephine) was used at the surgical site to reduce local bleeding.
The surgical site was trichotomized and scrubbed with iodine. An incision approximately 20mm long was made in the scalp along the sagittal suture and full-thickness flap, including periosteum, was reflected, exposing the calvarial bone. Afterwards, two transosseous defects standardized with 4mm each in diameter were created in the center of the parietal bone without damaging the dura mater. A 4mm trephine bur (Neodent, Curitiba, PR, Brazil) was used to create the defects under constant irrigation with sterile physiological solution, to prevent the overheating of bone margins. The periosteum and skin were then sutured for total coverage using 4-0 nylon point sutures (Ethicon, Johnson & Johnson, São José dos Campos, SP, Brazil).

Three days after surgery, the animals were divided into 2 groups of 16 animals each. To the experimental group, PTH group, 40µg/kg of PTH was given (1-34) (Sigma-Aldrich, St. Louis, MO) prepared in 1% acetic acid, injected subcutaneously, 3 times a week for 4 weeks. The control group (CTL group) received the same volume of the vehicle according to figure 1. The intermittent PTH schedule and dose used in the present study were based on previous study (6-8). Neither antibiotics nor anti-inflammatory drugs were administered after the surgery.

Acetaminophen (Paracetamol, Abbott Laboratories, São Paulo, São Paulo, Brazil) was used for pain control.

- Radiographic Procedures
After 4 weeks of treatment, the animals were sacrificed through overdose of anesthetics. Sections of bone tissue, including the surgical sites, were removed with
701bur (Neodent, Curitiba, PR, Brazil) under constant irrigation and fixed in 4% neutral formalin solution for 72h. All samples were radiographed using a dental x-ray unit (GE-1000) with an exposure time of 0.1 seconds and 31x41mm dental radiographic film (Insight Film, Eastman Kodak, Rochester, NY) and radiographs were densitometrically measured through aluminum step-wedge equivalent thickness (Al eq.). The mean values of an optical density were obtained from 5 measurements of the defect area.

- Histological Procedures
After the radiographic procedures, all samples were demineralized in a 5% EDTA/phosphate buffered saline solution for 60 days and embedded in paraffin (15). Five-µm thick sections including the center of circular defects were stained with Hematoxylin and Eosin. Paraffin serial sections were measured using an image analysis system (Image-Pro, Media Cybernetics, Silver Spring, MD and Program KS400, Kotron Elektron GmbH, Eching, Germany). The residual bone defect was defined as the distance of the bone margins after the treatment period (Fig. 2A). In the presence of areas of new bone formation between the margins, the total measurement was calculated deducting the new bone island-like formations (Fig. 2B).

- Statistical Analysis
Student’s t test was used for the comparison between experimental and control groups. The data were submitted to statistical analysis and p values lower than 0.05 were considered significant (BioEstat ver.5.0, Belém, PA, Brazil).

Results
- Clinical observations
No adverse events were observed during the healing interval. After 4 weeks, the defects in PTH group were smaller and the edges were more irregular than in the CTL group. Bone regeneration occurred in form of islands-like, more evident characteristics in the PTH group (Fig. 2D) compared to the CTL group (Fig. 2C).

Neither of the specimens exhibited osseous continuity in both edges of the defect after treatment for 4 weeks.

- Histological Findings
The histological observations through light microscopy showed that in the PTH group, the bone defects were filled with new bone formation and thick fibrous tissue (Fig. 2B, D and Fig. 3B). In comparison, the CTL group showed that the bone defect was filled mainly with fibrous tissue (Fig. 3A) and a little island-like new bone formation between the margins of the initial defect (Fig. 2C).

Bone Histomorphometric Analysis
The histomorphometric analysis of the residual defect showed that samples from the PTH group presented mean of 1.5mm ±0.7 in diameter; for the CTL group,

Fig. 2. Photomicrographs illustrating the section of critically-sized defect in calvaria of Wistar rat from different groups stained with hematoxylin and eosin. A) Black line indicates residual bone defect measured in CTL group (original magnification 35x). B) Black line indicates residual bone defect measured in PTH group (original magnification 35x). C) Arrowheads indicate fibrous tissue and arrow indicates island-like of new bone in the CTL group (original magnification 35x). D) Arrowheads indicate fibrous tissue and arrows indicate island-like of new bone in the CTL group (original magnification 25x). β = Bone.

Fig. 3. Photomicrographs of defect in calvaria of Wistar rat from different groups stained with hematoxylin and eosin, original magnification 600x. Histological details of the CTL group in A and PTH group in B. Arrowheads indicate osteoblasts, FT = fibrous tissue, β = Bone.

Fig. 1. Animal Experiments demonstrate the adaptation time, beginning treatments (PTH and CTL groups), surgery (Calvaria defects), and the time of sacrifice.
the mean diameter was 1.98mm ±0.6 at 4 weeks post-surgery. There were statistically significant intergroup differences (p<0.05).

**Radiodensitometric Analysis**

Statistical analysis (p<0.05) of optical density revealed significant differences among the PTH group (2.1Al eq. ±0.04) and the CTL group (1.8Al eq. ±0.06).

**Discussion**

Recombinant human PTH (1-34) has been approved in the United States as monotherapy for the treatment of postmenopausal women with osteoporosis. Since PTH has been approved for the treatment of osteoporosis, a number of questions have arisen and PTH, in combination with other antiresorptive agents, has also been used for the treatment of osteoporosis (16-18). However, clinical administration of PTH alone is a potential therapy that has been shown to enhance and accelerate bone formation in bone fractures, regions surrounding dental implants (19,20) and in fenestrated mandibular defect (8).

The critically-sized bone defect has been defined as the size of an osseous defect that does not heal spontaneously with bone during the lifetime of the animal (21). Aalami et al. (22) demonstrated that the full-thickness 3, 4 and 5mm diameter in mice’s calvarial defect is not completely healed after 8 weeks.

In this study, we used a critically-sized 4mm calvarial defect in rats that were ten weeks old in the begging of the experiment. The treatment with intermittent PTH administration was given for 4 weeks and as expected, in both groups, PTH and CTL, there was an incomplete healing of the defects in this period studied. However, it was possible to observe the presence of new bone formation as islands-like between the margins of the initial 4mm defect.

It has been demonstrated that with the PTH intermittent treatment, it was possibly to prevent bone loss and restore bone mass in ovariectomized rats (23). Shirahata et al. (20) evaluated the influence of intermittent PTH (1-34) administration on the healing process after the placement of titanium screw implants in ovariectomized rats. The authors found that the density of bone around implants in the PTH group was almost the same found in the Sham operated group after 56 days of implantation, suggesting that the PTH treatment might be useful to improve clinical results after dental implantation.

Our previous work showed that the PTH (1-34) treatment using 40 µg/kg, 3 times a week, was able to protect the tooth site from periodontitis-induced bone loss and promoted significant reduction in the number of inflammatory cells at the marginal gingival area in ovariectomized rats (6,7).

Another investigation of our research team (8) demonstrated the PTH (1-34) administration was effective to induce bone formation, increase bone density, increase the amount of callus formed and also to accelerate the callus reabsorption, an increase in the number of osteoclasts present in the callus region, corroborating with other studies (9,12-14,24).

We also investigated the bone mineral density (BMD) that is widely used to evaluate alterations in the balance between osteoblastic bone formation and osteoclastic bone resorption (25). The measurement of BMD through radiographic densitometry has been performed in a number of studies, and its efficacy has been confirmed (25-27). Radiographic densitometry analysis is an important tool for the research evaluation because it is a rapid and low-cost method, and can produce results which are similar to those of dual-energy x-ray absorptiometry (25).

Our study was the first to use radiographic densitometry for the analysis of the intermittent PTH treatment in calvarial defect. We demonstrated that the PTH (1-34) intermittent treatment increased the BMD in rat calvaria critically-sized defect model. These results reinforce the histological observations due to, possibly a speculation, bone collagen during the mineralization phase, and changes in bone turnover could be expected to affect the quality of the bone, corroborating in a similar way with our previous study observed in the characteristics of collagen fibers from the periodontal ligament visualized through polarizing light microscopy (8). Garnes et al. (28) demonstrated that the PTH treatment changed type-I collagen isomerization (28).

Stancoven et al. (13) demonstrated that with PTH (1-34) administered (15 µg/kg) daily on calvarial defect (8mm) analyzed through radiographic and histologic exams, bone formation was slightly increased in the PTH group without a membrane and in the PTH group with a membrane. Andreassen and Cacciafesta (14) reported that daily PTH (1-34) administration (60pg/kg) for 5 weeks enhanced mechanical strength of healing rat’s calvarial defects (5mm) covered with expanded polytetrafluoroethylene membranes, and increased the dry weight of the newly-formed tissue inside the defect.

We demonstrated that treatment with a lower frequency of PTH injections, 3 times a week, for 4 weeks using dose PTH at 40µg/kg, was able to contribute to the acceleration of the healing process in the absence of some type of membrane to isolate the defect (4mm). We also demonstrated an increase in optical density measurements (bone mineral density) in the PTH group; samples suggested that PTH treatment contributed to bone formation with a higher amount of mineral and/or fibrous tissue when compared with the CTL group. These results were associated with the frequent observation of “island-like” format of new bone in the PTH group and a possible organization of the new collagen fibers, as previously demonstrated (8,28).
In conclusion, the present study reinforced the anabolic potential of PTH (1-34) intermittent treatment alone, without the utilization of any coadjuvant, suggesting that it is possible to increase the process of bone regeneration by accelerating the healing process in rat’s calvarial defects.

References
1. Cunha MJ, Esper LA, Sbrana MC, de Oliveira PG, do Valle AL, de Almeida AL. Effect of low-level laser on bone defects treated with bovine or autogenous bone grafts: in vivo study in rat calvaria. Biomed Res Int. 2014;2014:104230.
2. Ahn SH, Kim CS, Suk HJ, Lee YJ, Choi SH, Chai JL, et al. Effect of recombinant human bone morphogenetic protein-4 with carries in rat calvarial defects. J Periodontol. 2003;74:787-97.
3. Blom EJ, Klein-Nulend J, Yin L, van Waas MA, Burger EH. Transforming growth factor, incorporated in calcium phosphate cement stimulates osteotransduction in rat calvarial bone defects. Clin Implants Dent Relat Res. 2001:12:609-16.
4. Marden LJ, Fan RS, Pierce GF, Reddi AH, Hollinger JO. Platelet-derived growth factor inhibits bone regeneration induced by osteogenin, a bone morphogenetic protein, in rat craniotomy defects. J Clin Invest. 1993;92(6):2897-905.
5. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993;14(6):690-709.
6. Barros SP, Silva MAD, Somerman MJ, Nociti Jr FH. Parathyroid hormone protects against periodontitis-associated bone loss. J Dent Res. 2003;82:791-95.
7. Marques MR, da Silva MA, Manzi FR, Cesar-Neto JB, Nociti FH Jr, Barros SP. Effect of intermittent PTH administration in the periodontitis-associated bone loss in ovariectomized rats. Arch Oral Biol. 2005;50:421-9.
8. Vasconcelos DFP, Marques MR, Benatti BB, Barros SP, Nociti Júnior FH, Novaes PD. Intermittent parathyroid hormone administration improves periodontal healing in rats. J Periodontol. 2014;85:721-8.
9. Jilka R, Weinten RS, Belido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999;104:439-46.
10. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;10:1434-41.
11. Andreassen TT, Fledelius C, Ejercsted C, Olundh. Increase in calvarial bone defect in testing bone-regenerating materials. J Craniofac Surg. 2004;114:713-20.
12. Whitchfield MJ, Morley P, Ross V, Isaacs RJ, Rixon RH. Restoration of severely depleted femoral trabecular bone in ovariectomized rats by parathyroid hormone-(1-34). Calcif Tissue Int. 1995;56:227-31.
13. Augustine M, Horwitz MJ. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis. Curr Opin Endocrinol. 2013;11:400-6.
14. Luciano MP, Nelson-Filho P, Morse L, Battaglino R, Watanabe PC, Silva RA, et al. Radiodensitometric and DXA analyses for the measurement of bone mineral density after systemic alendronate therapy. Braz Oral Res. 2013;27:252-7.
15. Rowshan HH, Parham MA, Baur DA, McEntee RD, Cauley JE, Carriere DT, et al. Effect of intermittent systemic administration of recombinant parathyroid hormone (1-34) on mandibular fracture healing in rats. J Oral Maxillofac Surg. 2010;68:260-7.
16. Bosch C, Melsen B, Vargervik K. Importance of the critical-size bone defect in testing bone-regenerating materials. J Craniofac Surg 1998;9:310–316.
17. Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2006;91:1370-5.
18. Winarno AS, Kyvernitakis I, Hadji P. Successful treatment of 1-34 parathyroid hormone (PTH) after failure of bisphosphonate therapy in a complex case of pregnancy associated osteoporosis and multiple fractures. Z Geburtshilfe Neonatol. 2014;218:171-3.
19. Skripitz R, Aspenberg P. Implant fixation enhanced by intermittent treatment with parathyroid hormone. J Bone Joint Surg Br. 2001;83:437-40.
20. Shirotia T, Tashiro M, Ohno K, Yamaguchi A. Effect of intermittent parathyroid hormone (1-34) treatment on the bone response after placement of titanium implants into the tibia of ovariectomized rats. J Oral Maxillofac Surg. 2003;61(4):471-80.
21. Schmitz JP, Hollinger JO. The critical size defect as an experimental model for craniofacial bony nonunions. Clin Orthop Relat Res. 1986(205):299-308.
22. Aalami OO, Nacamuli RP, Lenton KA, Cowan CM, Fang TD, Fong KD, et al. Applications of a mouse model of calvarial healing: differences in regenerative abilities of juveniles and adults. Plast Reconstr Surg. 2004;114:713-20.
23. Whitfield M, Morley P, Ross V, Isaacs RJ, Rixon RH. Restoration of severely depleted femoral trabecular bone in ovariectomized rats by parathyroid hormone-(1-34). Calcif Tissue Int. 1995;56:227-31.
24. Augustine M, Horwitz MJ. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis. Curr Osteoporos Rep. 2013;11:400-6.
25. Luciano MP, Nelson-Filho P, Morse L, Battaglino R, Watanabe PC, Silva RA, et al. Radiodensitometric and DXA analyses for the measurement of bone mineral density after systemic alendronate therapy. Braz Oral Res. 2013;27:252-7.
26. Rowshan HH, Parham MA, Baur DA, McEntee RD, Cauley JE, Carriere DT, et al. Effect of intermittent systemic administration of recombinant parathyroid hormone (1-34) on mandibular fracture healing in rats. J Oral Maxillofac Surg. 2010;68:260-7.
27. Erdogan O, Incik KE, Benlidayi ME, Seydaoglu G, Kolecski S. Dental and radiographic findings as predictors of osteoporosis in postmenopausal women. Geriatr Gerontol Int. 2009;9:155-64.
28. Garnero P, Bauer DC, Mareu E, Bilezikian JP, Greenspan SL, Rosen C, et al. Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study. J Bone Miner Res. 2008;23:1442-8.

Conflict of Interest
The authors declare that they have no conflict of interests.

Acknowledgments
Research supported by the Comissão de Aperfeiçoamento de Pessoal do Nível Superior (CAPES). We thank teacher Abilio Borghi for the grammar review of the manuscript.